Related Experiment Videos
Persistent neonatal hyperinsulinemic hypoglycemia in two siblings successfully treated with diazoxide
Helvetica Paediatrica Acta
|December 1, 1986
Summary
Diazoxide effectively managed persistent neonatal hyperinsulinemic hypoglycemia in two siblings for extended periods. This treatment avoided the need for pancreatic surgery, offering a safe, long-term therapeutic option.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Neonatal Medicine
Background:
- Persistent neonatal hyperinsulinemic hypoglycemia (PNHH) is a rare but serious condition causing severe hypoglycemia in newborns.
- PNHH requires prompt and effective management to prevent long-term neurological complications.
- Surgical intervention, such as partial pancreatectomy, is often considered for refractory cases.
Observation:
- Two siblings presented with persistent neonatal hyperinsulinemic hypoglycemia.
- The condition required long-term management strategies.
- Treatment efficacy and safety were monitored over several years.
Findings:
- Diazoxide, at a dosage of 10 mg/kg/d, successfully controlled hypoglycemia in both siblings.
- One sibling was managed for eight years, and the other for one year, with diazoxide.
- No serious adverse side effects were reported during the treatment period.
Implications:
- Diazoxide represents a viable and safe medical management option for persistent neonatal hyperinsulinemic hypoglycemia.
- This approach can potentially obviate the need for invasive pancreatic surgery in select pediatric patients.
- Long-term diazoxide therapy may be a sustainable strategy for managing PNHH, improving patient outcomes.